RenovoRx (NASDAQ:RNXT) Upgraded at Zacks Investment Research

RenovoRx (NASDAQ:RNXTGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday, Zacks.com reports.

According to Zacks, “RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California. “

Shares of RenovoRx stock opened at $1.84 on Friday. RenovoRx has a twelve month low of $1.50 and a twelve month high of $16.74. The company’s fifty day moving average is $2.41 and its 200 day moving average is $3.94.

RenovoRx (NASDAQ:RNXTGet Rating) last issued its quarterly earnings data on Friday, May 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.16). As a group, sell-side analysts predict that RenovoRx will post -1 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Board of Trustees of The Leland Stanford Junior University bought a new position in shares of RenovoRx during the 3rd quarter valued at $368,000. Citadel Advisors LLC bought a new stake in RenovoRx in the 3rd quarter worth $73,000. Two Sigma Securities LLC bought a new stake in RenovoRx in the 3rd quarter worth $108,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of RenovoRx during the 3rd quarter valued at about $125,000. Finally, Virtu Financial LLC bought a new stake in shares of RenovoRx during the 4th quarter valued at about $64,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

RenovoRx Company Profile (Get Rating)

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.

Further Reading

Get a free copy of the Zacks research report on RenovoRx (RNXT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.